BH holds the position of chief executive officer at Oncorena, a small oncology company with no trials or products related to IgA nephropathy. BH is an adjunct professor at the University of Gothenburg. In 2018–22, BH was employed as global programme head at Novartis, leading teams in immunology and transplantation, but not in nephrology. In 2015–18, BH led a team creating a nephrology portfolio (including iptacopan currently being tested for IgA nephropathy) at Novartis. In 2001–15, BH was chair and professor of nephrology at the University of Gothenburg, and senior consultant at the Sahlgrenska University Hospital.